Common Contracts
3 similar Transition Services Agreement contracts by Cancer Genetics, Inc, Interpace Diagnostics Group, Inc.
EX-10.1 5 ex10-1.htm EXECUTION VERSION TRANSITION SERVICES AGREEMENTTransition Services Agreement • May 5th, 2020 • Delaware
This Transition Services Agreement (this “Agreement”) is made as of the 15th day of July, 2019 (the “Effective Date”), by and between Cancer Genetics, Inc., a Delaware corporation (“CGI”) and Interpace BioPharma, Inc., a Delaware corporation (“Buyer”). Buyer and CGI are sometimes referred to herein collectively, as the “Parties” and individually, each a “Party”.
TRANSITION SERVICES AGREEMENTTransition Services Agreement • July 19th, 2019 • Cancer Genetics, Inc • Services-medical laboratories • Delaware
This Transition Services Agreement (this “Agreement”) is made as of the 15th day of July, 2019 (the “Effective Date”), by and between Cancer Genetics, Inc., a Delaware corporation (“CGI”) and Interpace BioPharma, Inc., a Delaware corporation (“Buyer”). Buyer and CGI are sometimes referred to herein collectively, as the “Parties” and individually, each a “Party”.
TRANSITION SERVICES AGREEMENTTransition Services Agreement • July 19th, 2019 • Interpace Diagnostics Group, Inc. • Surgical & medical instruments & apparatus • Delaware
This Transition Services Agreement (this “Agreement”) is made as of the 15th day of July, 2019 (the “Effective Date”), by and between Cancer Genetics, Inc., a Delaware corporation (“CGI”) and Interpace BioPharma, Inc., a Delaware corporation (“Buyer”). Buyer and CGI are sometimes referred to herein collectively, as the “Parties” and individually, each a “Party”.
